Form 4: Hinge Health CFO Sells Shares Under 10b5-1 Plan

Hinge Health's Chief Financial Officer, James Budge, sold 781 shares of Class A Common Stock for $44.78 per share under a pre-arranged trading plan.

Summary

• James Budge, Chief Financial Officer of Hinge Health, Inc. (HNGE), reported a sale of company stock.
• The transaction involved the disposition of 781 shares of Class A Common Stock.
• The shares were sold at a price of $44.78 per share.
• Following this transaction, James Budge beneficially owns 524,467 shares of Class A Common Stock directly.
• The sale was executed on November 20, 2025, pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be perceived negatively, the execution under a Rule 10b5-1 plan indicates a pre-scheduled transaction for personal financial management rather than a reaction to new material information, thus mitigating negative sentiment.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, though this is mitigated by the pre-planned nature.

Industry Context

This insider transaction by Hinge Health's CFO is a routine disclosure for publicly traded companies. Such sales, especially when executed under a Rule 10b5-1 plan, are common for executives managing personal finances and diversifying holdings, and typically do not reflect a change in the company's operational performance or strategic direction within the digital health or musculoskeletal care industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small volume of shares sold relative to the company's total outstanding shares and the pre-planned nature of the sale. Could lead to minor, temporary market speculation if not fully understood.

Key Dates

Keywords

Hinge Health, HNGE, James Budge, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Class A Common Stock